Chemokine Mechanisms in Chronic Pelvic Pain

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01676857

Enrollment

147

Registered

2012-08-31

Start date

2010-05-31

Completion date

2019-01-24

Last updated

2019-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Prostatitis With Chronic Pelvic Pain Syndrome, Prostatitis

Keywords

chronic pain, prostatitis, pelvic pain

Brief summary

The purpose of this study is to identify biomarkers that can be utilized in the diagnosis of chronic pelvic pain syndrome in men.

Detailed description

Chronic pelvic pain is the hallmark of patients with chronic pelvic pain syndrome (CPPS), a non-bacterial category of prostatitis that is a significant source of morbidity in American men. The cause of CPPS is unknown and there is a lack of convenient biomarkers for diagnosis of this syndrome. This project will examine the expression of biomarkers in expressed prostatic fluid from adult men with and without a diagnosis of CPPS. Thus our specific aim is to validate the use of the chemokines MCP-1 and MIP-1alpha and mast cell tryptase as biomarkers for CPPS in humans and correlate their levels with CPPS symptoms.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* CP/CPPS group inclusion criteria Patients are eligible for the study if they meet the following criteria: * Participant has signed and dated the appropriate Informed Consent document. * Agreed to participate in Study procedures. * Participant is at least 18 years of age. * Participant reports a response of at least 1 on the pain, pressure or discomfort scale (SYM-Q, Question #1). * Participant reports pain or discomfort in any of the 8 domains of the Male Genitourinary Pain Index (MGUPI) (items 1a, 1b, 1c, 1d, 2a, 2b, 2c, 2d). * These CP/CPPS symptoms been present for the majority of the time during any 3 months in the previous 6 months.

Exclusion criteria

* Participant has an on-going symptomatic urethral stricture. * Participant has an on-going neurological disease or disorder affecting the bladder or bowel fistula. Participant has a history of cystitis caused by tuberculosis, radiation therapy or Cytoxan/cyclophosphamide therapy. * Participant has augmentation cystoplasty or cystectomy. * Participant has a history of cancer (with the exception of skin cancer). * Participant has current major psychiatric disorder or other psychiatric or medical issues that would interfere with study participation (e.g. dementia, psychosis, upcoming major surgery, etc). * Participant diagnosed with unilateral orchialgia, without pelvic symptoms. * Participant has a history of transurethral microwave thermotherapy (TUMT), transurethral needle ablation (TUNA), balloon dilation, prostate cryo-surgery, or laser procedure. Control group

Design outcomes

Primary

Measure	Time frame	Description
Correlation of cytokines/chemokines/proteins with CPPS symptoms	Over the period of a year	Cytokines/chemokines/proteins will be correlated with symptom scores from patients in a longitudinal fashion.

Countries

United States

Outcome results